Study finds certain MS therapies may not slow disability progression.

A recent study published in the medical journal Neurology has found that certain medications used to treat primary progressive multiple sclerosis (MS) may not slow the progression of disability. The study looked at two infusion therapies, rituximab and ocrelizumab, which target a protein called CD20 found on white blood cells. The researchers found no difference in the amount of time before disability worsened between those taking the medications and those not receiving treatment. The study suggests that there should be a constant evaluation of MS therapies to determine if the benefits outweigh the risks for people with primary progressive MS. [Extracted from the article]